Corporate - Media & Press - Press Release
Arrayit Corporation Completes Installation of Patented Manufacturing Technology in Russia
Global Sales Expansion Targets Life Sciences and Diagnostics Opportunities in the World’s Largest Country
Source: Arrayit Corporation
On Monday March 15, 2010, 7:00 am EDT
SUNNYVALE, CA--(Marketwire - 03/15/10) - Arrayit Corporation (OTC.BB: ARYC - News), a global leader in life sciences and healthcare technology, announced today that the company has completed installation of its patented microarray manufacturing technology in Saint Petersburg, Russia. Arrayit Founder and Executive Vice President Todd Martinsky coordinated the installation with representatives from ChemBio, the company's distributor in Moscow. The Russian Academy for Medical Sciences in Saint Petersburg and the Institute of Gene Biology of the Russian Academy of Sciences in Moscow hosted warmly received lectures by Mr. Martinsky.
Arrayit's patented manufacturing technology empowers customers to fabricate microarrays, glass chips that contain nearly invisible spots of genes and proteins from the human body. Microarrays are used to identify variations in the genetic blueprint that correlate with human disease and to diagnose infectious disease, cancer and other illnesses by detecting minute quantities of biomarkers present in human serum. Arrayit VIP microarrays allow testing of up to 100,000 patients on a single device as a means of delivering highly cost-effective healthcare information to millions of people.
Arrayit Chairman and CEO Rene Schena stated, "This strategic installation underscores our commitment to the utilization of Arrayit technology on a global scale." The Russian Federation, the largest country in the world, comprises more than 11% of the earth's land area and extends across 11 time zones.
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.